SCHEMBL6375370

SCHEMBL6375370

O=C(c1ccc(Cl)cc1)c1ccc(OCCOCc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.58
NR4A2 P43354 2/20 0.55
ALDH1A1 P00352 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
KDM4E B2RXH2 1/20 0.54
POLB P06746 1/20 0.54
RECQL P46063 1/20 0.54
GAA P10253 2/20 0.54
PPARG P37231 1/20 0.52
NR4A1 P22736 1/20 0.51
NR4A3 Q92570 1/20 0.51
L3MBTL1 Q9Y468 4/20 0.51
HTT P42858 2/20 0.51
LMNA P02545 3/20 0.50
MAPT P10636 3/20 0.50
MAOB P27338 2/20 0.50
MRGPRX4 Q96LA9 1/20 0.50
PKM P14618 1/20 0.50
MAOA P21397 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5727237 0.91 SRD5A2 (0.65) SRD5A2NR4A2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6378011 0.90 SRD5A2 (0.63) SRD5A2NR4A2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL5725683 0.87 L3MBTL1 (0.62) NR4A2ALDH1A1SMN1; SMN2GAAPPARG
SCHEMBL8503299 0.87 SRD5A2 (0.77) SRD5A2NR4A2ALDH1A1SMN1; SMN2POLB
SCHEMBL6373824 0.86 SRD5A2 (0.58) SRD5A2NR4A2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL25686462 0.84 NR4A1 (0.55) SRD5A2NR4A2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL24047115 0.84 NR4A2 (0.73) SRD5A2NR4A2SMN1; SMN2POLBNR4A1
SCHEMBL8503301 0.82 NR4A2 (0.74) SRD5A2NR4A2ALDH1A1SMN1; SMN2POLB
SCHEMBL9397994 0.82 DRD2 (0.51) NR4A2PPARGMAOBPPARA
SCHEMBL2984321 0.81 MAOB (0.74) NR4A2ALDH1A1SMN1; SMN2GAANR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6875775-B2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD (FI) 2005-04-05 US disclosed
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD. 2003-12-04 US disclosed
US-6576645-B1 Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect HORMOS MEDICAL OY LTD (FI) 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators ESR2, ESR1, GPER1 SRD5A2 92/4885NR4A2 36/4885ALDH1A1 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.